AI assistant
Replimune Group, Inc. — Director's Dealing 2020
Jul 11, 2020
33193_dirs_2020-07-10_1eeeeeac-3efc-4370-ab91-0c918dd7b7bc.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Replimune Group, Inc. (REPL)
CIK: 0001737953
Period of Report: 2020-07-09
Reporting Person: Coffin Robert (Director, President & Chief R&D Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-07-09 | Common Stock | S | 145500 | $22.32 | Disposed | 2048368 | Direct |
| 2020-07-09 | Common Stock | S | 24250 | $21.02 | Disposed | 2024118 | Direct |
Footnotes
F1: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 7, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
F2: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.8167 to $22.7299.
F3: Following the sales reported on this Form 4, the reporting person continues to beneficially own 2,024,118 shares of the Issuer's common stock. The reporting person also holds options to acquire 977,599 shares of the Issuer's common stock, 384,438 of which are exercisable as of the date hereof.